glp 1 ra tablet Foundayo (orforglipron) – First Oral Non-Peptide GLP-1 FDA-approved April 2026 for chronic weight management. Once-daily with no fasting requirement, stepwise dosing up to 17.2 mg, and meaningful weight reduction in 1 pathway FDA approves Foundayo, an oral

: 1 -

Practical considerations: cost, access, and lifestyle Cost and coverage: Prices vary widely and insurance coverage differs by plan and by indication (diabetes vs weight management)

Ozempic is a medication originally developed for type 2 diabetes, but it has also become widely known for its role in supporting weight loss in eligible patients

Why cell therapy will benefit Policy-level endorsement of clinical use: The measures explicitly call for promoting clinical application of innovative therapies, which lowers administrative and institutional barriers for hospitals and companies to deploy cell therapies in regulated clinical settings